Yes wow_老虎社区_美港股上老虎

2021-01-24

Yes wow

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?<blockquote>吉利德 (GILD) 过去一个月上涨 19%：未来会怎样？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":319912782,"tweetId":"319912782","gmtCreate":1611471320846,"gmtModify":1703750548235,"author":{"id":3556787208739110,"idStr":"3556787208739110","authorId":3556787208739110,"authorIdStr":"3556787208739110","name":"Wapapapow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Yes wow</body></html>","htmlText":"<html><head></head><body>Yes wow</body></html>","text":"Yes wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/319912782","repostId":2105459536,"repostType":4,"repost":{"id":"2105459536","kind":"news","pubTimestamp":1611300933,"share":"https://www.laohunote.com/m/news/2105459536?lang=zh_CN&edition=full","pubTime":"2021-01-22 15:35","market":"us","language":"en","title":"Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?<blockquote>吉利德 (GILD) 过去一个月上涨 19%：未来会怎样？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2105459536","media":"Zacks","summary":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and","content":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.<blockquote>股份吉利德科学公司在过去的一个月里上升了19.3%。该公司在 2020 年经历了多事之秋，并因其冠状病毒治疗 Veklury（瑞德西韦）而备受关注。美国食品和药物管理局已全面批准Veklury用于治疗COVID-19患者，欧盟委员会（“EC”）亦已授予其有条件上市许可。</blockquote> The stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.<blockquote>该股在过去一年中上涨了 7.2%，而该行业的增长率为 13.9%。</blockquote> <img src=\"https://static.tigerbbs.com/af3ba6e3f673d6fd0f236d1fd5a528aa\" tg-width=\"620\" tg-height=\"283\"><blockquote></blockquote> Last week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.<blockquote>上周，由于冠状病毒大流行的恶化推动了 Veklury 的销售，该公司增加了 2020 年年度销售指引。目前预计 2020 年产品总销售额为 243-243.5 亿美元，高于之前指导的 230-235 亿美元。鉴于最近的 COVID-19 激增，由于住院率和治疗率高于预期，Veklury 销售额出现增长。Veklury 的销售额估计为 28-28.25 亿美元。</blockquote> Total product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.<blockquote>考虑到 Biktarvy 的强劲吸收率，不包括 Veklury 在内的产品总销售额预计为 215 亿至 215.25 亿美元，但部分被 Truvada 在美国的独家经营权丧失以及 COVID-19 主要对吉利德暴露前预防（“PrEP”）和慢性丙型肝炎病毒（“HCV”）专营权的影响所抵消。</blockquote> While Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines fromPfizer&nbsp;and others might lead to a decline in sales eventually.<blockquote>虽然随着过去几个月疫情恶化，Veklury 的销售强劲，但疫苗的推出辉瑞而其他的最终可能会导致销售额下降。</blockquote> Nevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes ofGlaxo. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.<blockquote>尽管如此，尽管面临来自 Biktarvy 等公司的激烈竞争，吉利德仍可能保持其由 Biktarvy 领导的强大 HIV 专营权的势头。葛兰素Descovy（恩曲他滨200 mg和替诺福韦阿拉芬酰胺25 mg片剂；F/TAF）作为预防选择的标签扩展促进了该治疗的销售。FDA早些时候还将Truvada作为PrEP的适应症扩大到包括高危青少年。新疗法的批准加强了特许经营权。</blockquote> We remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.<blockquote>我们提醒投资者，其曾经利润丰厚的 HCV 特许经营权销售额大幅下降，促使其专注于 HIV 特许经营权、Yescarta 和其他更新的渠道。</blockquote> Gilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.<blockquote>吉利德正在向肿瘤学领域多元化发展。为此，它以约 210 亿美元收购了 Immunomedics，并进行战略合作，进军利润丰厚的肿瘤学领域。2020 年 4 月，吉利德以 49 亿美元收购了 Forty Seven，并获得了 magrolimab，这是一种正在临床开发中的研究性单克隆抗体，用于治疗多种血液癌症。吉利德还收购了Pionyr Immunotherapeutics，Inc.49.9%的股权，这是一家在免疫肿瘤学领域追求新型生物学的私营公司。</blockquote> It has also collaborated withNovo Nordisk&nbsp;for developing treatments for non-alcoholic steatohepatitis (NASH).<blockquote>它还与诺和诺德用于开发非酒精性脂肪性肝炎（NASH）的治疗方法。</blockquote> Biggest Tech Breakthrough in a Generation<blockquote>一代人以来最大的技术突破</blockquote> Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.<blockquote>成为这种新型设备的早期投资者之一，专家称这种设备可能会像电力的发现一样对社会产生影响。目前的技术很快就会过时，被这些新设备所取代。在此过程中，预计将创造 2200 万个就业岗位，创造 12.3 万亿美元的经济活动。</blockquote> A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.<blockquote>随着这项新技术的加速推出，少数几只股票的涨幅可能最大。早期投资者可能会看到类似于 20 世纪 90 年代购买微软的收益。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?<blockquote>吉利德 (GILD) 过去一个月上涨 19%：未来会怎样？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead (GILD) Up 19% in the Past Month: What Lies Ahead?<blockquote>吉利德 (GILD) 过去一个月上涨 19%：未来会怎样？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nZacks2021-01-22 15:35\n\n</h4>\n</header>\n<article>\nShares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.<blockquote>股份吉利德科学公司在过去的一个月里上升了19.3%。该公司在 2020 年经历了多事之秋，并因其冠状病毒治疗 Veklury（瑞德西韦）而备受关注。美国食品和药物管理局已全面批准Veklury用于治疗COVID-19患者，欧盟委员会（“EC”）亦已授予其有条件上市许可。</blockquote> The stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.<blockquote>该股在过去一年中上涨了 7.2%，而该行业的增长率为 13.9%。</blockquote> <img src=\"https://static.tigerbbs.com/af3ba6e3f673d6fd0f236d1fd5a528aa\" tg-width=\"620\" tg-height=\"283\"><blockquote></blockquote> Last week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.<blockquote>上周，由于冠状病毒大流行的恶化推动了 Veklury 的销售，该公司增加了 2020 年年度销售指引。目前预计 2020 年产品总销售额为 243-243.5 亿美元，高于之前指导的 230-235 亿美元。鉴于最近的 COVID-19 激增，由于住院率和治疗率高于预期，Veklury 销售额出现增长。Veklury 的销售额估计为 28-28.25 亿美元。</blockquote> Total product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.<blockquote>考虑到 Biktarvy 的强劲吸收率，不包括 Veklury 在内的产品总销售额预计为 215 亿至 215.25 亿美元，但部分被 Truvada 在美国的独家经营权丧失以及 COVID-19 主要对吉利德暴露前预防（“PrEP”）和慢性丙型肝炎病毒（“HCV”）专营权的影响所抵消。</blockquote> While Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines fromPfizer&nbsp;and others might lead to a decline in sales eventually.<blockquote>虽然随着过去几个月疫情恶化，Veklury 的销售强劲，但疫苗的推出辉瑞而其他的最终可能会导致销售额下降。</blockquote> Nevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes ofGlaxo. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.<blockquote>尽管如此，尽管面临来自 Biktarvy 等公司的激烈竞争，吉利德仍可能保持其由 Biktarvy 领导的强大 HIV 专营权的势头。葛兰素Descovy（恩曲他滨200 mg和替诺福韦阿拉芬酰胺25 mg片剂；F/TAF）作为预防选择的标签扩展促进了该治疗的销售。FDA早些时候还将Truvada作为PrEP的适应症扩大到包括高危青少年。新疗法的批准加强了特许经营权。</blockquote> We remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.<blockquote>我们提醒投资者，其曾经利润丰厚的 HCV 特许经营权销售额大幅下降，促使其专注于 HIV 特许经营权、Yescarta 和其他更新的渠道。</blockquote> Gilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.<blockquote>吉利德正在向肿瘤学领域多元化发展。为此，它以约 210 亿美元收购了 Immunomedics，并进行战略合作，进军利润丰厚的肿瘤学领域。2020 年 4 月，吉利德以 49 亿美元收购了 Forty Seven，并获得了 magrolimab，这是一种正在临床开发中的研究性单克隆抗体，用于治疗多种血液癌症。吉利德还收购了Pionyr Immunotherapeutics，Inc.49.9%的股权，这是一家在免疫肿瘤学领域追求新型生物学的私营公司。</blockquote> It has also collaborated withNovo Nordisk&nbsp;for developing treatments for non-alcoholic steatohepatitis (NASH).<blockquote>它还与诺和诺德用于开发非酒精性脂肪性肝炎（NASH）的治疗方法。</blockquote> Biggest Tech Breakthrough in a Generation<blockquote>一代人以来最大的技术突破</blockquote> Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.<blockquote>成为这种新型设备的早期投资者之一，专家称这种设备可能会像电力的发现一样对社会产生影响。目前的技术很快就会过时，被这些新设备所取代。在此过程中，预计将创造 2200 万个就业岗位，创造 12.3 万亿美元的经济活动。</blockquote> A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.<blockquote>随着这项新技术的加速推出，少数几只股票的涨幅可能最大。早期投资者可能会看到类似于 20 世纪 90 年代购买微软的收益。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead\">Zacks</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2105459536","content_text":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.\nThe stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.\n\nLast week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.\nTotal product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.\nWhile Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines fromPfizer and others might lead to a decline in sales eventually.\nNevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes ofGlaxo. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.\nWe remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.\nGilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.\nIt has also collaborated withNovo Nordisk for developing treatments for non-alcoholic steatohepatitis (NASH).\nBiggest Tech Breakthrough in a Generation\nBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.\nA select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":730,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/319912782"}